LIPOCINE INC (LPCN)
US53630X2036 - Common Stock
We assign a fundamental rating of 4 out of 10 to LPCN. LPCN was compared to 197 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for LPCN as it has an excellent financial health rating, but there are worries on the profitability. LPCN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
LPCN had negative earnings in the past year.
LPCN had a negative operating cash flow in the past year.
In the past 5 years LPCN always reported negative net income.
LPCN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
LPCN has a Return On Assets (-35.24%) which is in line with its industry peers.
LPCN's Return On Equity of -37.44% is fine compared to the rest of the industry. LPCN outperforms 63.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.24% | ||
| ROE | -37.44% | ||
| ROIC | N/A |
ROA(3y)-33.65%
ROA(5y)-49.96%
ROE(3y)-37.29%
ROE(5y)-91.07%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for LPCN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
LPCN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LPCN has more shares outstanding
Compared to 5 years ago, LPCN has more shares outstanding
There is no outstanding debt for LPCN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 2.18 indicates that LPCN is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.18, LPCN is in the better half of the industry, outperforming 70.77% of the companies in the same industry.
There is no outstanding debt for LPCN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.18 |
ROIC/WACCN/A
WACC9.02%
2.3 Liquidity
A Current Ratio of 16.99 indicates that LPCN has no problem at all paying its short term obligations.
LPCN's Current ratio of 16.99 is amongst the best of the industry. LPCN outperforms 90.26% of its industry peers.
LPCN has a Quick Ratio of 16.99. This indicates that LPCN is financially healthy and has no problem in meeting its short term obligations.
LPCN's Quick ratio of 16.99 is amongst the best of the industry. LPCN outperforms 90.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 16.99 | ||
| Quick Ratio | 16.99 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 22.62% over the past year.
The Revenue has grown by 756.97% in the past year. This is a very strong growth!
EPS 1Y (TTM)22.62%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q197.06%
Revenue 1Y (TTM)756.97%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q14005.87%
3.2 Future
The Earnings Per Share is expected to grow by 34.51% on average over the next years. This is a very strong growth
Based on estimates for the next years, LPCN will show a very strong growth in Revenue. The Revenue will grow by 79.61% on average per year.
EPS Next Y50.17%
EPS Next 2Y34.51%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year166.07%
Revenue Next 2Y170.17%
Revenue Next 3Y138.17%
Revenue Next 5Y79.61%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LPCN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LPCN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as LPCN's earnings are expected to grow with 34.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.51%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for LPCN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LIPOCINE INC
NASDAQ:LPCN (5/17/2024, 7:11:11 PM)
After market: 6 -0.04 (-0.66%)6.04
+0.29 (+5.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap32.31M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.24% | ||
| ROE | -37.44% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.19
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 16.99 | ||
| Quick Ratio | 16.99 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)22.62%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y50.17%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)756.97%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y